Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Gemtesa

Phase 1Small molecule

UUniversity of Missouri-Columbia

Gemtesa is one of 15 small molecule programs targeting Hypoxia. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

14

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoxiaRecruiting

HypoxiaPhase 1

Recruiting

Competition

Competitive Landscape

20 competitors in Hypoxia

#DrugCompanyPhaseTrials

Actos

Diamox

Inderal

WWyeth-Lederle Vaccines

Zyrtec

Neptazane

WWyeth-Lederle Vaccines

Citicoline

UUniversity of Texas Southwestern Medical Center

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Nitrostat

VViatris Specialty LLC

Calcium

Ciprofol

Haisco Pharmaceutical Group Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Hypoxia

NCT06417177

Clinical

Trials by Indication[1]

Hypoxia1 trial

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

Recruiting·UUniversity of Missouri-Columbia·Phase 1·NCT06417177·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gemtesa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gemtesa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gemtesa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Missouri-Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Missouri-Columbia

Related News